A Three Part Study of MGV354 in Ocular Hypertension or Glaucoma

• ClinicalTrials.gov Identifier: NCT02743780
• Recruitment Status: Completed
• First Posted: April 19, 2016
• Results First Posted: August 31, 2017
• Last Update Posted: July 2, 2018
• Sponsor: Alcon Research
• Collaborator: Novartis Institute for BioMedical Research
• Information provided by (Responsible Party): Alcon Research

Study Description

Brief Summary:

The purpose of this study is to determine if the clinical profile of topical-ocular MGV354 merits further development for the indication of lowering intraocular pressure (IOP).

Condition or disease	Intervention/treatment	Phase
Ocular Hypertension; Open-Angle Glaucoma	Drug: MGV354 ophthalmic suspension; Drug: MGV354 placebo	Phase 1; Phase 2

Detailed Description:

Part 1 will evaluate the safety and tolerability of single ascending doses of MGV354 compared to placebo in healthy male and female subjects. Part 2 will evaluate the safety and tolerability of MGV354 in a multiple ascending dose design (two highest tolerated doses from Part 1) compared to placebo when administered for 7 days to patients with ocular hypertension or glaucoma. Part 3 will explore the safety, tolerability and efficacy of a single dose level of MGV354 (maximum tolerated dose) compared to placebo when administered for 7 days in patients with ocular hypertension or glaucoma.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 191 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Double (Participant, Investigator)
• Primary Purpose: Other
• Official Title: A Three Part, First-in-human, Randomized, Double-masked, Placebo-Controlled, Safety, Tolerability and Early Efficacy Study of MGV354 in Healthy Subjects and in Patients With Ocular Hypertension or Glaucoma
• Actual Study Start Date: March 2, 2016
• Actual Primary Completion Date: September 20, 2016
• Actual Study Completion Date: September 20, 2016

Arms and Interventions

Arm	Intervention/treatment
Experimental: MGV354; Part 3: MGV354 ophthalmic suspension, 1 drop in both eyes once per day for 7 days	Drug: MGV354 ophthalmic suspension
Placebo Comparator: Placebo; Part 3: MGV354 placebo, 1 drop in both eyes once per day for 7 days	Drug: MGV354 placebo; Inactive ingredients used as placebo comparator

Outcome Measures

Primary Outcome Measures :

1. Part 3: Change in Diurnal IOP (Averaged Over 8 AM, 10 AM, Noon, 4 PM, and 8 PM) From Baseline to Day 8 [ Time Frame: Baseline, Day 8 ]
   IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and reported in mmHg. Diurnal IOP was defined as the average of the five time points measured (8 AM, 10 AM, noon, 4 PM, and 8 PM). Baseline diurnal IOP was the average of IOP measurements obtained at the 2 eligibility visits. Change from baseline was calculated by taking the change at each time point from baseline to Day 8 and averaging the available changes. A more negative change from baseline indicates a greater improvement, i.e., a reduction of IOP. Only one eye (study eye) contributed to the analysis.
2. Part 3: Change in IOP From Baseline to Day 8 at 8 AM, 10 AM, Noon, 4 PM, and 8 PM [ Time Frame: Baseline, Day 8 ]
   IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and reported in mmHg. Baseline IOP was the average of IOP measurements obtained at the 2 eligibility visits. Change from baseline was calculated by taking the change at each time point from baseline to Day 8. A more negative change from baseline indicates a greater improvement, i.e., a reduction of IOP. Only one eye (study eye) contributed to the analysis.

Secondary Outcome Measures :

1. Part 3: Change From Baseline in IOP at 36 Hours and 48 Hours Post Day 7 Administration [ Time Frame: Baseline, up to Day 9 ]
   IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and reported in mmHg. Baseline IOP was the average of IOP measurements obtained at the 2 eligibility visits. Change from baseline was calculated by taking the change at each time point from baseline to Day 8 and averaging the available changes. A more negative change from baseline indicates a greater improvement, i.e., a reduction of IOP. Only one eye (study eye) contributed to the analysis.
2. Part 1: Maximum Observed Concentration [Cmax (ng/mL)] [ Time Frame: Pre-dose, .5, 2, 4, 6, 12, 24, 48, 72, 96, 120 hours post-dose, and Day 7 post-dose ]
   Based on plasma samples collected at pre-determined nominal time points, dependent on observed concentrations. Approximately 2 mL of venous blood was collected at each time point. Cmax is reported as mass/volume.
3. Part 1: Time to Reach Maximum Concentration [Tmax (h)] [ Time Frame: Pre-dose, .5, 2, 4, 6, 12, 24, 48, 72, 96, 120 hours post-dose, and Day 7 post-dose ]
   Based on plasma samples collected at pre-determined nominal time points, dependent on observed concentrations. Approximately 2 mL of venous blood was collected at each time point.
4. Part 1: Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration [AUClast (ng*h/mL)] [ Time Frame: Pre-dose, .5, 2, 4, 6, 12, 24, 48, 72, 96, 120 hours post-dose, and Day 7 post-dose ]
   Based on plasma samples collected at pre-determined nominal time points, dependent on observed concentrations. Approximately 2 mL of venous blood was collected at each time point. AUClast is reported as mass*time/volume.
5. Part 1: Area Under the Plasma Concentration-time Curve From Time Zero to 120 Hours Post Dose [AUC0-120 (ng*h/mL)] [ Time Frame: Pre-dose to 120 hours post-dose ]
   Based on plasma samples collected at pre-determined nominal time points, dependent on observed concentrations. Approximately 2 mL of venous blood was to be collected at each time point.
6. Part 1: Area Under the Concentration-time Curve From 0 to Infinity [AUCinf (ng*h/mL)] [ Time Frame: Pre-dose to 120 hours post-dose ]
   Based on plasma samples collected at pre-determined nominal time points, dependent on observed concentrations. Approximately 2 mL of venous blood was to be collected at each time point.
7. Part 1: Terminal Elimination Half-life [t1/2 (h)] [ Time Frame: Pre-dose to 120 hours post-dose ]
   Based on plasma samples collected at pre-determined nominal time points, dependent on observed concentrations. Approximately 2 mL of venous blood was to be collected at each time point.
8. Part 2: Maximum Observed Concentration [Cmax (ng/mL)] [ Time Frame: Up to Day 7 ]
   Based on plasma samples collected at pre-determined nominal time points, dependent on observed concentrations. Approximately 2 mL of venous blood was collected at each time point. Cmax is reported as mass/volume.
9. Part 2: Time to Reach Maximum Concentration [Tmax (h)] [ Time Frame: Up to Day 7 ]
   Based on plasma samples collected at pre-determined nominal time points, dependent on observed concentrations. Approximately 2 mL of venous blood was collected at each time point.
10. Part 2: Area Under the Concentration-time Curve From 0 to the End of the Dosing Interval Tau [AUCtau (ng*h/mL)] [ Time Frame: Up to Day 7 ]
    Based on plasma samples collected at pre-determined nominal time points, dependent on observed concentrations. Approximately 2 mL of venous blood was collected at each time point. AUCtau is reported as mass*time/volume.
11. Part 2: Accumulation Ratio (Racc) [ Time Frame: Day 7 ]
    Accumulation Ratio was derived using Cmax on Day 7 versus Cmax on Day 1. Approximately 2 mL of venous blood was collected at each time point.
12. Part 3: Observed Concentration at 12 Hours Following Drug Administration [C12 (ng/mL)] [ Time Frame: Up to Day 8 ]
    Based on plasma samples collected at pre-determined nominal time points, dependent on observed concentrations. Approximately 2 mL of venous blood was collected at each time point. C12 is reported as mass/volume.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

• Documented informed consent.
• Part 1: 18 to 70 years of age;
• Parts 2 and 3: 18 years of age or older;
• Able to communicate well with the investigator and understand and comply with the requirements of the study;
• Body Mass Index (BMI) between 18 and 39;
• In case of contact lens wear, willing to remove lenses 30 minutes before the first assessment until the end of the study. Corrective spectacles may be worn as needed.
• Sitting vital signs (systolic and diastolic blood pressure and pulse rate) within normal ranges as specified in the protocol;
• Part 1 (Healthy Volunteers): In good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at screening.
• Parts 2 and 3 (Patients): Diagnosed with open-angle glaucoma or confirmed ocular hypertension; mean IOP measurements in at least one eye after washout as specified in the protocol
• Other protocol-specified inclusion criteria may apply.

Exclusion criteria:

• History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes;
• History of or current presence of clinically significant ECG abnormalities or arrhythmias;
• History of malignancy of any organ system (other than localized basal cell carcinoma of the skin or in-situ cervical or breast cancer), treated or untreated, within the past 5 years;
• Known clinical history of heart failure, myocardial infarction, or stroke;
• Exposure during the four weeks preceding the Screening visit to any topical, inhaled, or systemic corticosteroids;
• Angle grade less than Grade 2 in either eye;
• Any abnormality, including corneal thickness > 620 microns, preventing reliable applanation tonometry;
• Pregnant or lactating women and women of child-bearing potential;
• Sexually active males must agree to use a condom during intercourse while taking drug and for 6 days after stopping MGV354 medication and should not father a child in this period;
• Positive HIV, Hepatitis B Ag or Hepatitis C Ab test result at Screening;
• Abnormal liver function tests;
• History or presence of impaired renal function;
• Part 1 (Healthy Volunteers): Use of any NEW prescription drugs or herbal supplements within four (4) weeks prior to initial dosing, and/or NEW over-the-counter (OTC) medication, dietary supplements (vitamins included) within two (2) weeks prior to initial dosing.
• Parts 2 and 3 (Patients): Patients with related disease condition(s) including any form of glaucoma other than open-angle glaucoma and pseudoexfoliation and/or pigment dispersion components; patients who cannot safely discontinue use of all topical ocular and/or systemic IOP-lowering medication according to protocol-specified Washout Schedule; patients with ocular diseases or conditions as specified in the protocol; patients taking certain medications as specified in the protocol;
• Other protocol-specified exclusion criteria may apply.

Contacts and Locations

Sponsors and Collaborators

Alcon Research

Novartis Institute for BioMedical Research

Investigators

• Study Director: Clinical Science Expert, NIBR; Novartis Institute for BioMedical Research

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Stacy R, Huttner K, Watts J, Peace J, Wirta D, Walters T, Sall K, Seaman J, Ni X, Prasanna G, Mogi M, Adams C, Yan JH, Wald M, He Y, Newton R, Kolega R, Grosskreutz C. A Randomized, Controlled Phase I/II Study to Evaluate the Safety and Efficacy of MGV354 for Ocular Hypertension or Glaucoma. Am J Ophthalmol. 2018 Aug;192:113-123. doi: 10.1016/j.ajo.2018.05.015. Epub 2018 May 24.

• Responsible Party: Alcon Research
• ClinicalTrials.gov Identifier: NCT02743780
• Other Study ID Numbers: MGV354-2201
• First Posted: April 19, 2016
• Results First Posted: August 31, 2017
• Last Update Posted: July 2, 2018
• Last Verified: August 2017

Keywords provided by Alcon Research:

Ocular Hypertension; Open-Angle Glaucoma; POAG; Glaucoma

Additional relevant MeSH terms:

Glaucoma; Glaucoma, Open-Angle; Ocular Hypertension; Hypertension; Vascular Diseases; Cardiovascular Diseases; Eye Diseases; MGV354; Enzyme Activators; Molecular Mechanisms of Pharmacological Action